Expression of CD133 on leukemia-initiating cells in childhood ALL.
نویسندگان
چکیده
Optimization of therapy for childhood acute lymphoblastic leukemia (ALL) requires a greater understanding of the cells that proliferate to maintain this malignancy because a significant number of cases relapse, resulting from failure to eradicate the disease. Putative ALL stem cells may be resistant to therapy and subsequent relapses may arise from these cells. We investigated expression of CD133, CD19, and CD38 in pediatric B-ALL. Cytogenetic and molecular analyses demonstrated that karyotypically aberrant cells were present in both CD133(+)/CD19(+) and CD133(+)/CD19(-) subfractions, as were most of the antigen receptor gene rearrangements. However, ALL cells capable of long-term proliferation in vitro and in vivo were derived from the CD133(+)/CD19(-) subfraction. Moreover, these CD133(+)/CD19(-) cells could self-renew to engraft serial nonobese diabetic-severe combined immunodeficient recipients and differentiate in vivo to produce leukemias with similar immunophenotypes and karyotypes to the diagnostic samples. Furthermore, these CD133(+)/CD19(-) ALL cells were more resistant to treatment with dexamethasone and vincristine, key components in childhood ALL therapy, than the bulk leukemia population. Similar results were obtained using cells sorted for CD133 and CD38, with only the CD133(+)/CD38(-) subfraction demonstrating xenograft repopulating capacity. These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
منابع مشابه
Comparison and comparison of CD133 gene expression in healthy individuals and people with leukemia
متن کامل
بررسی بیان شاخص‌های سطحی CD133، CD44 و ABCG2 در رده‌های سلولی ملانوما و ارتباط آنها با سلول‌های بنیادی سرطان
Background and Objective: Melanoma is the most deadly type of skin cancer that has a high potency and rapid metastasis to other organs. It appears that cancer stem cells (CSCs) are responsible for invasion and metastasis. The aim of this study was to investigate the expression of cancer stem cells candidate markers and their association with stemness features in mel...
متن کاملبررسی بیان شاخص‌های بنیادینگی ALDH1 و CD133 در رده‌های سلولی ملانوما A375 و D10
Background: The cancer stem cells (CSCs) are involved in invasion and metastasis of melanoma, the most lethal and aggressive form of skin cancer. In the present study, the expression of putative stem cell markers CD133 and ALDH1 were evaluated in melanoma cell lines and then the cells sorted based on the expression of these markers. Methods: In the present study expression of CD133 and A...
متن کاملQuantitative analyses of CD133 expression facilitate researches on tumor stem cells.
CD133 is regarded as a marker of tumor initiating cells in many tumors, including colorectal cancer. O'Brien and Ricci et al. have proved that in primary colorectal tumors there are colorectal tumor stem cells (initiating cells) which are marked by CD133 antigen. Using a genetic knockin lacZ reporter mouse model, Shmelkov et al. challenged this increasingly influential viewpoint and drew two im...
متن کاملCombination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer
The existence of specific cellular subpopulations within primary tumors with increased tumorigenic potential and chemotherapy resistance (tumor-initiating cells, TICs) holds great therapeutic implications. Resistant cells can remain quiescent for long periods and be responsible for local relapses and metastasis. We and others have previously described in non-small-cell lung cancer the presence ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 113 14 شماره
صفحات -
تاریخ انتشار 2009